UB-311, a novel UBITh(®) amyloid β peptide vaccine for mild Alzheimer's disease

INTRODUCTION: A novel amyloid β (Aβ) synthetic peptide vaccine (UB-311) has been evaluated in a first-in-human trial with patients of mild-to-moderate Alzheimer's disease. We describe translational research covering vaccine design, preclinical characterization, and phase-I clinical trial with s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chang Yi, Wang, Pei-Ning, Chiu, Ming-Jang, Finstad, Connie L., Lin, Feng, Lynn, Shugene, Tai, Yuan-Hung, De Fang, Xin, Zhao, Kesheng, Hung, Chung-Ho, Tseng, Yiting, Peng, Wen-Jiun, Wang, Jason, Yu, Chih-Chieh, Kuo, Be-Sheng, Frohna, Paul A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651432/
https://www.ncbi.nlm.nih.gov/pubmed/29067332
http://dx.doi.org/10.1016/j.trci.2017.03.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651432/
https://www.ncbi.nlm.nih.gov/pubmed/29067332
http://dx.doi.org/10.1016/j.trci.2017.03.005

Ejemplares similares